Form 8-K - Current report:
SEC Accession No. 0001193125-24-184249
Filing Date
2024-07-25
Accepted
2024-07-25 06:04:59
Documents
15
Period of Report
2024-07-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d860436d8k.htm   iXBRL 8-K 29971
2 EX-99.1 d860436dex991.htm EX-99.1 35141
6 GRAPHIC g860436g04j44.jpg GRAPHIC 16939
  Complete submission text file 0001193125-24-184249.txt   224656

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA dawn-20240723.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dawn-20240723_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dawn-20240723_pre.xml EX-101.PRE 11265
17 EXTRACTED XBRL INSTANCE DOCUMENT d860436d8k_htm.xml XML 3654
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005 650 484-0899
Day One Biopharmaceuticals, Inc. (Filer) CIK: 0001845337 (see all company filings)

EIN.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40431 | Film No.: 241139644
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)